JP2007520557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520557A5 JP2007520557A5 JP2006552178A JP2006552178A JP2007520557A5 JP 2007520557 A5 JP2007520557 A5 JP 2007520557A5 JP 2006552178 A JP2006552178 A JP 2006552178A JP 2006552178 A JP2006552178 A JP 2006552178A JP 2007520557 A5 JP2007520557 A5 JP 2007520557A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- progression
- immunoglobulin
- subject
- integrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (5)
- 腫瘍の増殖と、腫瘍の転移性進行と、腫瘍の転移の進展とのうちの少なくとも１つを阻害するための方法であって、
腫瘍の増殖と、腫瘍の転移とのうちの少なくとも１つを阻害するのに十分な量の抗−α４免疫グロブリンをそれを必要とする対象に投与する工程を含むことを特徴とする方法。 - 前記抗−α４抗体がα４β１インテグリンと、α４β７インテグリンとのうちの少なくとも１つに結合することを特徴とする請求項１に記載の方法。
- 前記腫瘍はリンパ腫であり、前記対象は１つまたはそれ以上の化学療法と、放射線療法とのうちの少なくとも１つで治療されることを特徴とする請求項１に記載の方法。
- 腫瘍の増殖と、腫瘍の転移性進行と、腫瘍の転移の進展とのうちの少なくとも１つを阻害するための併用療法であって、
抗−α４免疫グロブリンまたはα４インテグリンリガンドに対する免疫グロブリンを投与する工程と、
化学療法と、免疫療法と、放射線療法とのうちの少なくとも１つ、を含むことを特徴とする併用療法。 - 抗−α４免疫グロブリンを含む薬剤であって、それを必要とする対象に投与されると腫瘍の増殖と、腫瘍の転移性進行と、腫瘍の転移の進展とのうちの少なくとも１つを阻害する薬剤を調製するための使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54194604P | 2004-02-06 | 2004-02-06 | |
| US60/541,946 | 2004-02-06 | ||
| PCT/US2005/002860 WO2005076843A2 (en) | 2004-02-06 | 2005-02-03 | Methods and compositions for treating tumors and metastatic disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007520557A JP2007520557A (ja) | 2007-07-26 |
| JP2007520557A5 true JP2007520557A5 (ja) | 2008-05-22 |
| JP4996261B2 JP4996261B2 (ja) | 2012-08-08 |
Family
ID=34860234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552178A Expired - Fee Related JP4996261B2 (ja) | 2004-02-06 | 2005-02-03 | 腫瘍および転移性疾患を処置するための方法および組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050255118A1 (ja) |
| EP (2) | EP1718310A4 (ja) |
| JP (1) | JP4996261B2 (ja) |
| KR (1) | KR20070009581A (ja) |
| CN (1) | CN1946407B (ja) |
| AR (1) | AR047534A1 (ja) |
| AU (1) | AU2005213324B2 (ja) |
| BR (1) | BRPI0507451A (ja) |
| CA (1) | CA2555365A1 (ja) |
| EA (1) | EA009873B1 (ja) |
| IL (1) | IL177201A0 (ja) |
| MX (1) | MXPA06008746A (ja) |
| NO (1) | NO20063951L (ja) |
| NZ (1) | NZ584288A (ja) |
| PE (1) | PE20060009A1 (ja) |
| TW (1) | TWI375563B (ja) |
| UY (1) | UY28741A1 (ja) |
| WO (1) | WO2005076843A2 (ja) |
| ZA (1) | ZA200606557B (ja) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040732B (zh) | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| SI2177537T1 (sl) | 2004-01-09 | 2012-01-31 | Pfizer | Protitielesa proti MAdCAM |
| WO2007007152A2 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| EP2109460B1 (en) * | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
| EP2231185A4 (en) * | 2007-12-07 | 2012-06-27 | Elan Pharm Inc | METHOD AND COMPOSITIONS FOR TREATING LIQUID TUMORS |
| GB0800311D0 (en) * | 2008-01-09 | 2008-02-20 | Cytosystems Ltd | Apparatus and method for filtering biological material |
| WO2009129333A1 (en) * | 2008-04-15 | 2009-10-22 | Oxigene, Inc. | Methods for enhancing the efficacy of vascular disrupting agents |
| US20100158893A1 (en) * | 2008-12-19 | 2010-06-24 | Baxter International Inc. | Systems and methods for obtaining immunoglobulin from blood |
| WO2010121141A1 (en) * | 2009-04-17 | 2010-10-21 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
| US20110158982A1 (en) * | 2009-10-05 | 2011-06-30 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM |
| EP2625263B1 (en) | 2010-10-08 | 2020-03-11 | Terumo BCT, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| LT3326645T (lt) | 2010-10-25 | 2020-08-10 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai |
| KR20140072026A (ko) * | 2011-07-22 | 2014-06-12 | 페이실렉스 파마슈티컬스 인코포레이티드 | 암의 합성치사 및 치료 |
| US20160074337A1 (en) * | 2011-08-17 | 2016-03-17 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
| WO2014018913A2 (en) * | 2012-07-27 | 2014-01-30 | University Of Connecticut | Santacruzamate a compositions and analogs and methods of use |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| RU2527154C1 (ru) * | 2013-03-27 | 2014-08-27 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ повышения биодоступности цисплатина в саркому -45, индуцированную в эксперименте |
| CN105339390A (zh) * | 2013-04-29 | 2016-02-17 | Ogd2药物 | 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略 |
| JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
| WO2015112888A1 (en) | 2014-01-24 | 2015-07-30 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| JP6830059B2 (ja) | 2014-09-26 | 2021-02-17 | テルモ ビーシーティー、インコーポレーテッド | スケジュール化された細胞フィーディング |
| PL3215158T3 (pl) | 2014-11-07 | 2019-11-29 | Ai Therapeutics Inc | Apilimod do zastosowania do leczenia raka nerki |
| EP3215159B1 (en) | 2014-11-07 | 2021-07-21 | AI Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| EP3325662B1 (en) | 2015-07-17 | 2023-08-30 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
| EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | CELL EXPANSION |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| RU2650587C1 (ru) * | 2017-04-26 | 2018-04-16 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ модификации хронической болью злокачественного роста меланомы в16 у мышей |
| AU2018300189A1 (en) | 2017-07-14 | 2020-01-30 | Pfizer, Inc. | Antibodies to MAdCAM |
| JP2022500419A (ja) * | 2018-09-13 | 2022-01-04 | ンカルタ・インコーポレイテッドNkarta, Inc. | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| RU2765955C1 (ru) * | 2021-03-30 | 2022-02-07 | Елена Рудольфовна Милаева | Средство для ингибирования метастазирования в легких |
| RU2762730C1 (ru) * | 2021-03-30 | 2021-12-22 | Елена Рудольфовна Милаева | Средство для ингибирования метастазирования в легких |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| CA2072249C (en) | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| EP0678122B1 (en) | 1993-01-12 | 1999-07-28 | Biogen, Inc. | Recombinant anti-vla4 antibody molecules |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| AU3559695A (en) | 1994-09-30 | 1996-04-26 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| AU733692B2 (en) * | 1997-02-28 | 2001-05-24 | Regents Of The University Of California, The | Inhibition of cell-cell binding by lipid assemblies |
| MY153569A (en) * | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| PL203114B1 (pl) * | 1998-09-14 | 2009-08-31 | Regents Board Of | Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1 |
| EP2140881B1 (en) | 1999-12-16 | 2013-04-17 | Biogen Idec MA Inc. | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| WO2002045653A2 (en) * | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
| WO2002100429A1 (en) * | 2001-06-11 | 2002-12-19 | Transition Therapeutics Inc. | Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| AU2002356180A1 (en) * | 2001-08-06 | 2003-03-10 | The Regents Of The University Of California | Methods for inhibiting angiogenesis |
| PT1485127E (pt) * | 2002-02-25 | 2011-09-07 | Elan Pharm Inc | Administração de agentes para o tratamento de inflamação |
| WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
| EP1682179A4 (en) * | 2003-11-05 | 2008-09-03 | Palingen Inc | INCREASED CYTOTOXICITY OF CDIM BINDING ANTIBODY AGAINST B LYMPHOCYTES |
-
2005
- 2005-02-03 EP EP05712339A patent/EP1718310A4/en not_active Withdrawn
- 2005-02-03 US US11/049,365 patent/US20050255118A1/en not_active Abandoned
- 2005-02-03 EP EP11005763A patent/EP2394652A3/en not_active Withdrawn
- 2005-02-03 NZ NZ584288A patent/NZ584288A/en not_active IP Right Cessation
- 2005-02-03 MX MXPA06008746A patent/MXPA06008746A/es active IP Right Grant
- 2005-02-03 JP JP2006552178A patent/JP4996261B2/ja not_active Expired - Fee Related
- 2005-02-03 KR KR1020067018079A patent/KR20070009581A/ko active IP Right Grant
- 2005-02-03 CN CN2005800121486A patent/CN1946407B/zh not_active Expired - Fee Related
- 2005-02-03 BR BRPI0507451-7A patent/BRPI0507451A/pt not_active IP Right Cessation
- 2005-02-03 AU AU2005213324A patent/AU2005213324B2/en not_active Ceased
- 2005-02-03 CA CA002555365A patent/CA2555365A1/en not_active Abandoned
- 2005-02-03 WO PCT/US2005/002860 patent/WO2005076843A2/en active Application Filing
- 2005-02-03 ZA ZA200606557A patent/ZA200606557B/en unknown
- 2005-02-03 EA EA200601433A patent/EA009873B1/ru not_active IP Right Cessation
- 2005-02-04 UY UY28741A patent/UY28741A1/es unknown
- 2005-02-04 PE PE2005000129A patent/PE20060009A1/es not_active Application Discontinuation
- 2005-02-04 AR ARP050100431A patent/AR047534A1/es not_active Application Discontinuation
- 2005-02-05 TW TW094103833A patent/TWI375563B/zh not_active IP Right Cessation
-
2006
- 2006-08-01 IL IL177201A patent/IL177201A0/en unknown
- 2006-09-05 NO NO20063951A patent/NO20063951L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520557A5 (ja) | ||
| Selby et al. | Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. | |
| JP2008507530A5 (ja) | ||
| LTC2100614I2 (lt) | Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui | |
| RU2009149451A (ru) | Лечение антителами против vegf | |
| IL186303A (en) | 1h - benzamideimzole - 4 carboxyamides converted with quarterly carbon in position 2, the pharmaceutical composition containing it and its use for the preparation of a drug @ for the treatment @ of cancer | |
| DE602006019119D1 (de) | Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin | |
| JP2009539870A5 (ja) | ||
| CL2007001902A1 (es) | Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas. | |
| EP1742654A4 (en) | ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER | |
| JP2008524329A5 (ja) | ||
| Kelly et al. | Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. | |
| O'Reilly et al. | A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) | |
| Tam et al. | Safety and activity of the highly specific BTK inhibitor BGB-3111 in patients with indolent and aggressive non Hodgkin's lymphoma | |
| JP2006514116A5 (ja) | ||
| BRPI0806529A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta | |
| JP2015531396A5 (ja) | ||
| WO2007075706A3 (en) | Affinity optimized epha2 agonistic antibodies and methods of use thereof | |
| Fayad et al. | Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 study | |
| Reidy et al. | A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). | |
| EP1944039A4 (en) | ACTIVE AGENT FOR THE TREATMENT OF TUMORS AND ITS USE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS | |
| He et al. | Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients | |
| WO2007007152A3 (en) | Anti-madcam antibodies to treat metastatic cancers and chloroma | |
| Heymach et al. | Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC). | |
| Chow et al. | Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors. |